CMPXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Compass Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$0.83−0.03 (-2.91%)
Close on Oct 19, 2026
- Market cap
- $155.98M
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Compass Therapeutics has not reported a dividend
No dividend per share appears in Compass Therapeutics's annual filings since fiscal 2018.